DocMorris (DOCM.SW) Stock Price
DocMorris Price
Revenue has compounded at 5.7% per year over the past 15 years to 1.12 B CHF. Earnings per share have grown at 11.2% per year over the last 13 years. DocMorris's net margin stands at -12.0%, up from -13.1% several years earlier. Analysts set a median price target of 8.26 CHF, implying 27.8% below the current price. Of 13 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 187% above its 52-week low.
DocMorris stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of DocMorris over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how DocMorris stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing DocMorris's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | DocMorris Price |
|---|---|
| 9/25/2026 | 11.44 CHF |
| 9/24/2026 | 10.69 CHF |
| 9/23/2026 | 10.93 CHF |
| 9/22/2026 | 11.10 CHF |
| 9/21/2026 | 11.10 CHF |
| 9/18/2026 | 10.86 CHF |
| 9/17/2026 | 10.40 CHF |
| 9/16/2026 | 10.06 CHF |
| 9/15/2026 | 10.11 CHF |
| 9/14/2026 | 9.77 CHF |
| 9/11/2026 | 10.00 CHF |
| 9/10/2026 | 10.18 CHF |
| 9/9/2026 | 10.80 CHF |
| 9/8/2026 | 10.04 CHF |
| 9/7/2026 | 10.80 CHF |
| 9/4/2026 | 10.68 CHF |
| 9/3/2026 | 10.19 CHF |
| 9/2/2026 | 10.36 CHF |
| 9/1/2026 | 10.70 CHF |
| 8/31/2026 | 10.94 CHF |
| 8/28/2026 | 11.00 CHF |
| 8/27/2026 | 10.45 CHF |
| 8/26/2026 | 10.25 CHF |
| 8/25/2026 | 10.26 CHF |
| 8/21/2026 | 9.95 CHF |
| 8/20/2026 | 10.32 CHF |
| 8/19/2026 | 9.66 CHF |
| 8/18/2026 | 9.63 CHF |
| 8/17/2026 | 9.78 CHF |
| 8/14/2026 | 9.63 CHF |
DocMorris Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
DocMorris Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB CHF |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM CHF |
| EBITM CHF |
| EBIT MARGIN% |
| NET INCOMEM CHF |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.83 | 0.88 | 0.98 | 1.21 | 1.36 | 1.48 | 1.73 | 0.93 | 0.97 | 1.02 | 1.12 | 1.26 | 1.40 | 1.54 | 1.77 | 1.99 |
| -8.85 | 5.40 | 11.72 | 22.91 | 12.26 | 8.93 | 16.94 | -46.12 | 4.19 | 4.95 | 10.52 | 12.10 | 11.19 | 10.21 | 14.70 | 12.59 |
| 14.99 | 14.90 | 14.87 | 15.82 | 15.35 | 16.33 | 15.06 | 17.20 | 20.95 | 21.24 | 9.34 | 9.34 | 9.34 | 9.34 | 9.34 | 9.34 |
| 125.00 | 131.00 | 146.00 | 191.00 | 208.00 | 241.00 | 260.00 | 160.00 | 203.00 | 216.00 | 105.00 | 117.70 | 130.88 | 144.23 | 165.44 | 186.27 |
| 8.00 | -7.00 | -33.00 | -36.00 | -44.00 | -114.00 | -200.00 | 40.00 | -75.00 | -104.00 | -84.00 | -58.00 | -24.00 | 3.00 | 38.00 | 79.00 |
| 0.96 | -0.80 | -3.36 | -2.98 | -3.25 | -7.72 | -11.59 | 4.30 | -7.74 | -10.23 | -7.47 | -4.60 | -1.71 | 0.19 | 2.15 | 3.96 |
| 3.00 | -12.00 | -36.00 | -38.00 | -52.00 | -135.00 | -225.00 | -171.00 | 82.00 | -97.00 | -134.00 | -87.00 | -43.00 | -12.00 | 15.00 | 48.00 |
| -57.14 | -500.00 | 200.00 | 5.56 | 36.84 | 159.62 | 66.67 | -24.00 | -147.95 | -218.29 | 38.14 | -35.07 | -50.57 | -72.09 | -225.00 | 220.00 |
| 13.93 | 13.93 | 13.26 | 13.18 | 17.63 | 19.44 | 19.64 | 22.90 | 23.89 | 24.00 | 51.62 | 51.62 | 51.62 | 51.62 | 51.62 | 51.62 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales DocMorris generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue DocMorris retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare DocMorris's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares DocMorris has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against DocMorris's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
DocMorris stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
DocMorris Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
DocMorris business model & stock analysis
DocMorris SWOT Analysis
Strengths
Zur Rose Group AG has a strong brand presence and recognition in the pharmaceutical industry.
The company has a wide range of products and services, providing convenience and accessibility to customers.
Zur Rose Group AG benefits from economies of scale due to its large customer base and extensive distribution network.
Weaknesses
Zur Rose Group AG faces intense competition from both traditional brick-and-mortar pharmacies and other online pharmacies.
The company's profitability is dependent on reimbursement rates from healthcare insurance providers.
Zur Rose Group AG may also face challenges in gaining customer trust and loyalty due to the sensitive nature of the pharmaceutical industry.
Opportunities
The growing trend towards e-commerce and digitalization in the healthcare sector provides an opportunity for Zur Rose Group AG to expand its online presence.
The increasing demand for personalized healthcare services opens avenues for the company to offer tailored product recommendations and improved customer experience.
Zur Rose Group AG can explore partnerships and collaborations with healthcare providers and insurers to enhance its service offerings.
Threats
Regulatory changes and compliance requirements pose a significant threat to Zur Rose Group AG's operations and profitability.
The emergence of counterfeit drugs in the online market can tarnish the company's reputation and erode customer trust.
Changes in consumer behavior and preferences can impact the demand for online pharmaceutical services.
DocMorris Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
DocMorris historical P/E ratio, EBIT multiple, and P/S ratio
DocMorris annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down DocMorris's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in DocMorris's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare DocMorris's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
DocMorris shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current DocMorris forecasts and price targets in September 2026
Analyst Price Targets 2026DocMorris Earnings Calls
DocMorris Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 3/18/2027 | -0.59CHF | - | 654.80 MCHF | - | 2027 Q1 |
| 8/19/2026 | -3.71CHF | -1.10CHF | 596.50 MCHF | - | 2026 Q2 |
| 4/17/2026 | -CHF | - | 304.00 MCHF | - | 2026 Q1 |
| 8/19/2025 | -CHF | -2.11CHF | 301.40 MCHF | - | 2025 Q2 |
| 3/13/2025 | -2.55CHF | -1.59CHF | 514.27 MCHF | - | 2024 Q4 |
| 8/20/2024 | -2.55CHF | -1.59CHF | 514.27 MCHF | - | 2024 Q2 |
| 10/18/2023 | -0.52CHF | -2.46CHF | 642.00 MCHF | - | 2023 Q3 |
| 8/16/2023 | -0.52CHF | -2.46CHF | 642.00 MCHF | - | 2023 Q2 |
| 8/17/2022 | -4.95CHF | -4.08CHF | 971.00 MCHF | - | 2022 Q2 |
| 12/30/2021 | -3.81CHF | -15.37CHF | 958.00 MCHF | - | 2021 Q4 |
EESG©
Eulerpool ESG Scorecard© for the DocMorris stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
DocMorris shareholder structure
| % | Name |
|---|---|
9.71315% | |
4.88742% | |
3.20515% | |
3.01010% | |
1.81633% | |
1.08485% |
DocMorris Beneficial Ownership Filings (SEC 13D/G)
DocMorris Executives and Management Board
12 members · avg. age 56 · 17 % women
Mr. Walter Hess (60)
Chief Executive Officer, Member of the Executive Board, Head Germany
1.82 M CHF
Management
Mr. Daniel Wueest (55)
Chief Financial Officer
Mr. Kaspar Niklaus (57)
Chief Operations Officer, Member of the Executive Board
Mr. Pablo Ros Gomez (43)
Chief Technology Officer
Dr. Daniel Grigat
Head of Investor Relations and Sustainability · since 2022
Board of Directors
Mr. Walter Oberhaensli (67)
Non-Executive Chairman of the Board · since 1996
Prof. Stefan Feuerstein (70)
Non-Executive Independent Vice Chairman of the Board of Directors
Dr. Christian Mielsch (62)
Non-Executive Independent Member of the Board of Directors
Prof. Dr. Andrea Belliger (55)
Non-Executive Independent Member of the Board of Directors
Ms. Hu Rongrong (44)
Non-Executive Independent Member of the Board of Directors
Mr. Florian Seubert (50)
Non-Executive Independent Member of the Board of Directors
Frequently asked questions about DocMorris
The business model of Zur Rose Group AG is focused on providing pharmaceutical and healthcare services. As a leading online pharmacy in Europe, Zur Rose offers a wide range of products and services. The company operates in two segments, namely the Pharmacy and the Services segments. Through its online platform, Zur Rose enables customers to order prescription and over-the-counter drugs, as well as healthcare products, from the comfort of their homes. Additionally, Zur Rose provides services to healthcare professionals, such as logistics and wholesale services. Overall, Zur Rose's business model aims to enhance the accessibility and convenience of pharmaceutical and healthcare products for its customers.
Zur Rose Group AG is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Zur Rose Group AG in the market include established online pharmacy platforms such as Shop Apotheke and DocMorris, as well as traditional brick-and-mortar pharmacies. Zur Rose Group AG competes with these companies by offering a convenient and user-friendly online platform for customers to order prescription and over-the-counter medications. With its strong emphasis on customer service and a wide range of products, Zur Rose Group AG aims to stay competitive in the rapidly growing online pharmacy market.
The Zur Rose Group AG is a renowned Swiss company specializing in healthcare and pharmacy services. Founded in 1993 by Walter Oberhänsli, it started as a local pharmacy in Zurich. Over the years, Zur Rose Group AG expanded its operations and established itself as a prominent e-commerce platform for pharmaceuticals, providing customers with easy access to a wide range of healthcare products. The company has since grown into one of Europe's leading online pharmacies, serving millions of customers across multiple countries. With its commitment to innovation and customer-centric approach, Zur Rose Group AG continues to revolutionize the healthcare industry by combining digital solutions with traditional pharmaceutical services.
Zur Rose Group AG, a leading online pharmacy in Europe, has achieved several significant milestones. The company went public in 2017, making it the first publicly traded online pharmacy in Switzerland. In 2018, Zur Rose Group AG acquired the pharmacy business of medpex, Germany's second-largest online pharmacy. This strategic move strengthened its position in Europe's largest pharmaceutical market. In 2020, the company successfully completed the acquisition of Apotal, another prominent online pharmacy in Germany. These milestones demonstrate Zur Rose Group AG's commitment to expanding its market presence, enhancing customer access to high-quality healthcare products, and solidifying its position as a trusted online pharmacy leader.
Zur Rose Group AG is primarily present in countries and regions including Switzerland, Germany, and Austria.
Zur Rose Group AG is a leading online pharmacy and healthcare provider. With a strong focus on customer satisfaction and quality, the company aims to improve the health and well-being of its customers. Its corporate philosophy revolves around innovation, efficiency, and sustainability. By utilizing advanced technology and digital solutions, Zur Rose Group AG ensures seamless and convenient access to a wide range of pharmaceutical products and healthcare services. The company places great value on trust, reliability, and transparency, aiming to establish long-lasting relationships with its customers. Zur Rose Group AG's commitment to providing accessible and affordable healthcare sets it apart in the industry.
Analysts currently set an average price target of 9.52 CHF for the DocMorris stock (median: 8.26 CHF), implying -16.8 % versus the latest price. The consensus is based on 13 analyst ratings.
14 analysts currently rate the DocMorris stock: 1 recommend buying, 6 holding and 7 selling. For 2026, analysts expect DocMorris to generate revenue of 1.26 B CHF and earnings per share of -1.69 CHF.
Converted at the current exchange rate, the DocMorris share trades at 12.12 EUR (11.44 CHF).
The DocMorris share (DOCM.SW) is listed on 7 stock exchanges, including: London (0RRB.L), SIX (Zürich) (ROSE.SW), Frankfurt (ZRE.F), München (ZRE.MU), Düsseldorf (ZRE.DU).
The Zur Rose Group AG is a leading company in the healthcare sector and offers a wide range of products and services, ranging from pharmaceuticals to care products to medical advice and healthcare services. The company is headquartered in Switzerland and operates in several European countries, including Germany, Austria, France, Spain, and Italy. The core business of the Zur Rose Group AG is the online sale of prescription and over-the-counter medications. Customers can order their medications through the Zur Rose Group AG platform and have them delivered to their homes free of charge. In order to provide this service, the Zur Rose Group AG has built its own mail-order pharmacy that complies with all legal requirements and where all medications are checked by qualified pharmacists. In addition to the mail-order pharmacy, the Zur Rose Group AG also operates a number of local pharmacies, known as "DocMorris." These pharmacies also offer prescription and over-the-counter medications, as well as care products and advice from qualified pharmacists. The Zur Rose Group AG has set itself the goal of becoming the leading pharmacy brand in Europe and is therefore continuously expanding into new markets. Another important business area of the Zur Rose Group AG is healthcare services. Here, the company offers services such as medical advice over the phone, email, or live chat. The Zur Rose Group AG also operates its own health centers, where patients can receive medical advice and treatment, as well as various health checks and preventive examinations. In order to further expand its business, the Zur Rose Group AG has also invested in other areas in recent years. For example, the company has developed the platform "smartpatient," which supports patients in managing their health data and informing themselves about their illnesses and treatment options. In addition, the Zur Rose Group AG has a stake in the company Medpex, an online shop for pharmaceuticals and care products. Overall, the Zur Rose Group AG pursues a broad-based business model based on various pillars. The company benefits from the growing trend towards online commerce and digital healthcare. At the same time, the Zur Rose Group AG also relies on proven concepts such as local pharmacies to ensure comprehensive access to medications and healthcare services. In the future, the Zur Rose Group AG is likely to continue to grow strongly and further expand its position as one of the leading providers in the healthcare sector.
The expected revenue of DocMorris is 1.26 B CHF. This figure is based on current financial data and reflects the company's business performance.
The expected profit of DocMorris is -87.25 M CHF. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of DocMorris is currently -6.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the DocMorris stock.
The price-to-sales ratio (P/S) of DocMorris is currently 0.47. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the DocMorris stock.
The Eulerpool Quality Score for DocMorris is 2/10.
The ISIN of DocMorris is CH0042615283. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of DocMorris is A0Q6J0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of DocMorris is DOCM.SW. The ticker symbol is used to trade DocMorris shares on the stock exchange.
DocMorris paid dividends every year for the past 0 years.
DocMorris is assigned to the 'Non-cyclical consumption' sector.
The dividends of DocMorris are distributed in CHF.
DocMorris stock
DocMorris Peer Group
DocMorris Ticker
DocMorris FIGI
All fundamentals and in-depth analysis of DocMorris
Our stock analysis for DocMorris stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DocMorris. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.